within Pharmacolibrary.Drugs.ATC.J;

model J05AR03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.25,
    Cl             = 0.16999999999999998,
    adminDuration  = 600,
    adminMass      = 0.245,
    adminCount     = 1,
    Vd             = 0.096,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Tenofovir disoproxil and emtricitabine is a fixed-dose combination antiretroviral medication used for the treatment and prevention (pre-exposure prophylaxis, PrEP) of HIV-1 infection in adults and adolescents. Both drugs are reverse transcriptase inhibitors: tenofovir is a nucleotide analog, and emtricitabine is a nucleoside analog. The combination is currently approved and widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in healthy adult volunteers, steady-state, after oral administration under fasting conditions.</p><h4>References</h4><ol><li><p>Dando, TM, &amp; Wagstaff, AJ (2004). Emtricitabine/tenofovir disoproxil fumarate. <i>Drugs</i> 64(18) 2075–2084. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200464180-00005&quot;>10.2165/00003495-200464180-00005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15341498/&quot;>https://pubmed.ncbi.nlm.nih.gov/15341498</a></p></li><li><p>McGowan, IM, et al., &amp; Cranston, RD (2022). An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil Fumarate. <i>AIDS research and human retroviruses</i> 38(4) 279–287. DOI:<a href=&quot;https://doi.org/10.1089/AID.2021.0115&quot;>10.1089/AID.2021.0115</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34541872/&quot;>https://pubmed.ncbi.nlm.nih.gov/34541872</a></p></li><li><p>Thurman, AR, et al., &amp; Doncel, GF (2021). Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial. <i>EClinicalMedicine</i> 36 100893–None. DOI:<a href=&quot;https://doi.org/10.1016/j.eclinm.2021.100893&quot;>10.1016/j.eclinm.2021.100893</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34041459/&quot;>https://pubmed.ncbi.nlm.nih.gov/34041459</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AR03;
